Main > > >ARRHYTMIA. *

---

Cardio.>Arrhytmia. 3D Mapping System. Locate the Origin of Arrhythmias. ..
USA Clearance Date: 2017. 02.01.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2019. 02.24.




Cardio.>Arrhytmia. 3D NonInvasive Loca-lization System.
Intended>ACQuisition, Analysis, Display
& storage of cardiac electro-
physiology data and maps for
analysis by a physician.
Intended>Used as Pre-Procedure>Planning
tool for patients with structu-
rally normal hearts undergoing
ablation treatment for idiopa-
thic ventricular arrhythmias.
System Consists of a hand-held 3D came-
ra, & an off-the-shelf laptop
computer with proprietary soft-
ware.
System Uses MRI or CT Scan along with a
standard 12-lead ΕCG to computer-
generate color-coded 3D mapping
images of the heart to indicate
the area of earliest activation.
Using a 3D photograph of the pa-
tient s chest, an MRI or CT
(DICOM image), and a standard 12-
lead ECG, the system generates a
3D rendering of the patient s
heart with superimposed color
coding to indicate the area of
earliest activation.
EU Approval Year : 2017.
USA Approval Date: 2019. 06.26.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.07.




Cardio.>Arrhytmia. Atrial Fibrillation (AFi). Diag.: AI (Artificial Intelli- gence) Enabled Platform.
USA Launch Date: 2017. 03.16.
(*) Company; TradeMark & Web-Site
Available on Request.
UpDate: 2019. 07.04.




Cardio.>Arrhytmia. Atrial Fibrillation (AFi). Diag.: AI (Artificial Intelligen- ce) (1)+ECG (Electro CardioGram)+Digital
Stethoscope (2)
(1) USA Clearance Date: 2020. 01.28.
(*) Company; Patent (2); & Web-Sites
Acailable on Request.
UpDate: 2020. 02.04.




Cardio.>Arrhytmia. Atrial Fibrillation (AFi). Diag.: Cloud- & AI (Artificial Intelligence)-Powered ECG (Electro
Cardio Gram) Analysis.
EU Approval Date : ?
USA Approval Date: 2017. 07.05.
(*) Company; Patent & Product Web-
Site Available on Request.
UpDate: 2019. 02.25.




Cardio.>Arrhytmia. Atrial Fibrillation (AFi). Diag.: ECG Personal (Mobile) Single Lead.
USA Approval Date: ?
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.04.




Cardio.>Arrhytmia. Atrial Fibrillation (AFi). Diag.: High Resolution (HR) Imaging & Non-Contact Mapping System.
Detects & Displays both Standard Volta-
ge-based & HR "Dipole Density (Charge-
Source) Maps". The System uniquely com-
bines "UltraSound (US) Anatomy Construc-
tion" with ability to map the "Electri-
cal-Conduction" of each "HeartBeat" to
Identify Complex Arrhytmias across the
entire "Atrial Chamber". Following each Ablation Treat. the Heart can be "Re-
Mapped" in seconds to continually Visua-
lize any changes from the prior Mapping.
Individualized & Personalized Catheter
Ablation.
IntraCardiac Echocardiography (ICE) &
ElectroAnatomic Mapping Systems.
System ACQuires up to 115,000 Ultra-
Sound (US) Data Points/Minute to rapidly
create an Anatomic Reconstruction of a
chamber of heart & up to 150,000 Biopo-
tential samples/Second to create a 3D
map of cardiac electrical activity of whole chamber in real-time.
System allows ElectroPhysiologists to
tailor TREATs. for each individual pa-
tient & then adapt that TREAT. Iterati-
vely-on the fly-while the patient is
still in ElectroPhysiology (EP) lab.
With System, Physicians can create a
full-chamber, 360-Degree Look at the
Atrium in Real-Time for each individual
patient enabling truly customized TREAT.
for every case using an iterative map,
ablate, re-map, ablate strategy.
EU Approval Date : 2016. 05.04.
USA Approval Date: 2017. 10.24.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.26.




Cardio.>Arrhytmia. Atrial Fibrillation (AFi).
Mapping. AI-Enabled Electrographic Flow
(Analyze and Visualize the Flow of Action Potentials)
EU Approval Year: 2018.
(*) Company; Patents & Web-Site Avai-
Lable on Request.
UpDate: 2019. 07.04.



Cardio.>Arrhytmia. Atrial Fibrillation (AFi). Mapping. Cardiac System.
USA Launch Date: 2017. 01.12.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.01.




Cardio.>Arrhytmia. Atrial Fibrillation (AFi). Mapping. HD Grid Catheter SE (Sen sor Enabled).
EU Approval Date : 2017. 12.
USA Approval Date: 2018. 05.03.
(*) Company; Patent: TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.01.




Cardio.>Arrhytmia. Atrial Fibrillation (AFi). NonValvular AF (U)
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Apixaban Tablets.
Oral Factor Xa Inhibitor AntiCoagulant.
EU Approval Date: 2012. 11.20.
USA Approval Date: 2013. 02.01.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 01.29.




Cardio.>Arrhytmia. Atrial Fibrillation (AFi). NonValvular AF (D)
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Dabigatran Etexilate Capsules.
Oral Direct Thrombin Inhibitor AntiCoagulant
EU Approval Date : ?
USA Approval Date: 2010. 10.19.
Patent No. 01 Expiration Date: 2018. 02.18.
(*) Company; Patents; TradeMark & Web-Site Available on Request.
UpDate: 2018. 01.30.




Cardio.>Arrhytmia. Atrial Fibrillation (AFi). NonValvular AF (D)
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Dabigatran Etexilate Capsules.
Oral Direct Thrombin Inhibitor AntiCoagulant. REVERSAL: IdarucizuMAb
IV Injection 5 g.
USA Approval Date: 2015. 10.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 04.18.




Cardio.>Arrhytmia. Atrial Fibrillation
(AFi). NonValvular AF
(NVAF). Stroke/Systemic Embolism Risk
Reduction:
Left Atrial Appendage (LAA) Closure De-
vice. (U>Ab.)
EU Approval Date: 2013. 01.18.
(*) Company; Patents & TradeMark Avai-
lable on Request
UpDate: 2019. 03.03.




Cardio.>Arrhytmia. Atrial Fibrillation
(AFi). NonValvular AF
(NVAF). Stroke/Systemic Embolism Risk
Reduction:
Left Atrial Appendage (LAA) Closure De-
vice. (U>Bo.)
EU Approval Date : 2009.
USA Approval Date: 2015. 03.13.
(*) Company; Patents; TradeMark & Web-
Available on Request
UpDate: 2019. 03.04.




Cardio.>Arrhytmia. Atrial Fibrillation (AFi). NonValvular AF (D)
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Rivaroxaban Tablets.
Xa Inhibitor.
EU Approval Date : 2011. 12.19.
USA Approval Date: 2012. 11.02.
(*) Companies; Patents; TradeMark & Web-Site Available on Request.
UpDate: 2018. 02.04.




Cardio.>Arrhytmia. Atrial Fibrillation (AFi). NonValvular AF
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Warfarin Sodium Tablets.
(*) Company : Bristol Myers Squibb.
Patent : Expired
TradeMark: Coumadin
Web-Site : www.coumadin.bmscustomerconnect.com
UpDate: 2018. 02.02.




Cardio.>Arrhytmia. Atrial Fibrillation (AFi). Treat.: Quartz CF (Contact Force) Ablation Catheter SE (Sensor Enabled).
EU Approval Date : 2017. 05.09.
USA Approval Date: 2019. 01.21.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 02.28.




Cardio.>Arrhytmia. Atrial Fibrillation (AFi.) Treat.: RadioFrequency (RF) Abla- tion. Bipolar RF Clamps.
Persistent and Long-Standing Persistent
(Non-Paroxysmal) during Open-Heart Concomitant Coronary Artery Bypass Grafting (CABG) &/or Valve Replacement or Repair Procedures.
USA Approval Date: 2011. 12.14.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.17.




Cardio.>Arrhytmia. Atrial Fibrillation (AFi). Treat.: Sotalol IV.>
>1-day Hospital Outpatient Initiation &
faster Dose Escalations for existing
patients
>Reducing Hospital costs and improving
patient satisfaction
>Shortens the Hospital stay from 3 days
to 1 day
USA Approval Date: 2020. 03.10.
(*) Company; Patent & Web-Sites Avai-
lable on Request.
UpDate: 2020. 03.15.




Cardio.>Arrhytmia. Atrial Flutter (AFl). Treat.: Irrigated Ablation Catheter SE (Sensor Enabled).
USA Approval Date: 2017. 03.01.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.07.




Cardio.>Arrhytmia. Bradycardia. Diag.: ECG Personal (Mobile). Single Lead.
USA Approval Date: 2019. 04.23.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.04.




Cardio.>Arrhytmia. Diagnostics. 14 Day Wear P-Wave Centric ECG Patch Monitor.
CA Approval Date: 2020. 02.
EU CE Mark Date: 2020. 05.26.
USA Clearance Date: 2019. 09.06.
USA Launch Date : 2020. 01.23.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 05.27.




Cardio.>Arrhytmia. Diagnostics. By Com-bining:
- Cloud-based Data Analytics
- Machine-Learning capabilities &
- Wearable Biosensing Technology
Company Goal: be the leading provider of first-line Ambulatory Electrocardiogram, or ECG, Monitoring for patients at risk for Arrhythmias.
EU Approval Date : 2014. 12.03.
USA Approval Date: 2012. 02.06.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.23.




Cardio.>Arrhytmia. Remote Diagnostics & Monitoring System that replicates in-hospital telemetry data, right in the office, by giving physicians 24/7 on-demand access to full disclosure Holter, Event, and MCT (Mobile Cardiac Teleme- try) data via a HIPAA-compliant portal APP.
EU Approval Date : 2014. 01.08.
USA Approval Date: 2016. 03.16.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.22.




Cardio.>Arrhytmia. Tachycardia. Diag.: ECG Personal (Mobile). Single Lead.
USA Approval Date: 2019. 04.23.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.04.




Cardio.>ElectroPhysiology Device. Description: The non-invasive System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
System aims to minimize noise and artifacts, and acquire high-fidelity cardiac signals. Improving cardiac signals may potentially increase the diagnostic value of these signals, thereby possibly improving accuracy and efficiency of the EP studies and related procedures.
One of the most common reasons for an EP procedure is the diagnosis and treatment of atrial fibrillation. Atrial fibrilla- tion is the most common arrhythmia ..
USA Approval Date: 2018. 08.14.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 06.04




Cardio.>Left Atrial Appendage (LAA) Closure Device. (U>At.)
In Arrhytmia>Atrial Fibrillation (AFi.)
Patients.
EU >Approved.
JP >Approved.
USA>Launched.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.17.




Cardio.>Left Atrial Appendage (LAA) Closure Device. (U>Ab.)
Stroke Risk Reduction in NonValvular
AFi Patients.
EU Approval Date: 2013. 01.18.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2019. 03.03.




Cardio.>Left Atrial Appendage (LAA) Closure Device. (U>Bo.)
Stroke Risk Reduction in NonValvular
AFi Patients.
EU Approval Date : 2009.
USA Approval Date: 2015. 03.13.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.04.




DIAG.: Injectable Cardiac Monitor (ICM).
Next Gen.
USA FDA Clearance Date: 2019. 07.08.
(*) Company : BioTronik
TradeMark: BIOMONITOR III
Web-Site :
www.biotronik.com/en-
us/products/crm/arrhythmia-
monitoring/biomonitor-3
UpDate: 2019. 07.15.




DIAG.: Insertable Cardiac Monitor (ICM).
Paperclip-Sized Implantable Device.
Combines Smartphone Connectivity &
and Continuous, Remote Monitoring.
EU Approval Date : 2017. 05.08.
USA Approval Date : 2017. 10.23.
EU/USA Launch Date: 2019. 05.06.
(*) Company : Abbott.
TradeMark: Confirm Rx
Web-Site : www.confirmyourrhythm.com
UpDate: 2019. 07.03.




Treat.: Acebutolol.HCl Capsules. Generic
(*) Company: Mylan
UpDate: 2019. 02.25.




Treat.: Propranolol.HCl Inj. Generic.
(*) Company: Fresenius Kabi USA
UpDate: 2019. 02.20.




Treat.: Verapamil.HCl ER Tablets. Brand
(*) Company : Pfizer.
Patent : Expired
TradeMark: Covera-HS
UpDate: 2019. 02.25.




Treat.: Verapamil.HCl ER Tablets. Gene-
ric.
(*) Company: Mylan.
UpDate: 2019. 02.25.




Treat.: Verapamil.HCl ER Tablets. Gene-
ric.
(*) Company: Teva Pharma.





>ARRHYTMIA. *'s products
This section has no products